Edwards Lifesciences Corp

Edwards Lifesciences Corporation is a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. The company's business strategy revolves around imagining, building, and realizing a better future for patients with cardiovascular diseases. Edwards Lifesciences offers a range of medical technologies to treat advanced cardiovascular diseases, which are categorized into four main groups: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. The company's Transcatheter Aortic Valve Replacement offerings include the Edwards SAPIEN family of valves, which are used for minimally-invasive replacement of aortic heart valves. Edwards Lifesciences is the global leader in this field, with over one million patients' lives impacted since launch. The company also offers minimally invasive options for pulmonary valve replacement for patients with congenital heart disease. In the Transcatheter Mitral and Tricuspid Therapies segment, Edwards Lifesciences offers the PASCAL PRECISION and Cardioband transcatheter valve repair systems for mitral and tricuspid valve repair. The PASCAL PRECISION system is commercially available in Europe for mitral and tricuspid valve repair, and in the U.S. and Japan for degenerative mitral regurgitation patients. The company is also developing transcatheter replacement technologies for mitral and tricuspid valves. Edwards Lifesciences' Surgical Structural Heart offerings include the RESILIA tissue, which has published clinical data showing 99% freedom from structural valve deterioration through seven years, and the MITRIS RESILIA valve, which is now commercially available in Europe, the U.S., and Japan. The company's latest innovation, the MITRIS RESILIA valve, is designed to strengthen its leadership and positive impact on patients in the surgical structural heart market. The Critical Care segment of Edwards Lifesciences focuses on advanced hemodynamic monitoring systems used to measure a patient's heart function and fluid status in surgical and intensive care settings. The company's portfolio includes minimally-invasive and noninvasive technologies, such as the FloTrac and Acumen IQ sensors, ClearSight and Acumen IQ cuffs, and the ForeSight noninvasive tissue oximetry sensor. Edwards Lifesciences also supports clinical needs with well-established Swan-Ganz pulmonary artery catheters and arterial pressure monitoring products. The company competes with both established and newer technologies and therapies, including drug therapies. Edwards Lifesciences holds leadership positions due to its development and production of safe and effective therapies supported by rigorous clinical studies, innovative features, and extensive customer and clinical support. Edwards Lifesciences sells its products through direct sales forces and independent distributors. The company's sales and marketing approach varies depending on each country's size and state of development. In 2023, 58% of the company's net sales were derived from sales to customers in the United States, while 42% were derived outside of the United States. The company manufactures its products primarily in the United States, Singapore, Costa Rica, Ireland, and the Dominican Republic. The company's website is located at www.edwards.com, and its stock is traded on the New York Stock Exchange under the ticker symbol "EW."